Surprised many didn't appreciate this call. I thou

Surprised many didn't appreciate this call. I thought it was AWESOME.

- Data that they presented was clear, concise and painted a much fuller picture.

- Compassionate Use is being worked on. BIG.

- Trial with Remdesivir is BIG. It will bring us more attention from regulators/FDA and if/when we kick Remdesivir's ass in the results, it's going to force people's hands (FDA, perhaps GILD)

- NYSE uplisting is being worked on. This commentary cut both ways for me. They're talking to an investment bank and dilution was discussed. While this is good long term, it would seem to imply they don't believe a gov't grant is imminent. So that's a bummer.

- eIND for pediatric use is another bright spot.

- Enrollment pace isn't very good, but with the recent hospital additions, it looks like this should accelerate. Unfortunately, I'm highly doubtful we get any results prior to the end of June. Just being conservative.

- When asked about buyouts, NP didn't answer the question asked. I believe he was talking about partnerships, not a buyout. Most CEO's would never comment about a buyout. I hope he clarifies his answer quickly. Especially with all the legal trolls circling. Glad he's not even mentioning non-binding LOI's. They're meaningless.

- Distribution discussions ongoing. Waiting for more to enter the picture.

- I felt he skirted the question about reinvesting his stock proceeds and didn't answer the question asked. I remain of the opinion this did not happen simply because there's been no PR or SEC filing.